Stroke

Transient Ischemic Attack

University Hospital Basel

The "COSMOS"-Study (Copeptin in Osmoregulation and Stress Assessment)

Copeptin as a Novel Diagnostic and Prognostic Marker in the Management of Neurological and Neurosurgical Patients With Sodium Imbalance The "COSMOS"-Study (Copeptin in Osmoregulation and Stress Assessment)

University Hospital, Basel, Switzerland

Motor Neuron Disease

Primary Lateral Sclerosis

National Institutes of Health Clinical Center, 9000 Rockville Pike

Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study

Oxidative Stress in Motor Neuron Disease: COSMOS-PLS Add-On Study

National Institute of Neurological Disorders and Stroke (NINDS)

Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.

Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.

Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.

Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
400 mg Rifamycin SV dosage

400 mg Rifamycin SV Dosage

Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
800 mg Rifamycin SV dosage

800 mg Rifamycin SV Dosage

Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
1200 mg Rifamycin SV dosage

1200 mg Rifamycin SV Dosage

Total

Sex: Female, Male

Height (cm)

Weight (kg)

Axillary Temperature (°C)

The safety and preliminary efficacy data of the three doses of the new rifamycin SV formulation tested based upon the time elapsed from the ingestion of the 1st dose of study medication to the passage of the last unformed stool (TLUS)

Time to Last Unformed Stool (TLUS)

The evaluation of improvement in diarrhoea during a 48 hour interval is defined as a >50% reduction of bowel movements versus the baseline value

The Number of Patients Showing Improvement in Diarrhoea During a 48h Interval

The number of unformed stools passed per 24-h interval, after dosing

The Number of Unformed Stools Passed Per 24-h Interval

The patient having must meet all of the following criteria in order to be classified as "well": 48 hours with no unformed stools with a maximum of two soft stools and no clinical symptoms of infectious diarrhoea.

The Number of Patients Who Are Declared to be "Well"

A treatment failure is defined as clinical deterioration or worsening of symptoms or illness continuing after 120 h following the first dose.

Number of Participants With Treatment Failure

Patients were considered to have recovered if fewer than three unformed stools were passed in the previous 24 hours and no symptom of enteric infection were present.

cosmos/atrophy

The "COSMOS"-Study (Copeptin in Osmoregulation and Stress Assessment)

Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study

Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea

科学支持的最完整的草药数据库